|
|
|
|
|
|
Sponsored by: |
Astellas Pharma Inc |
Information provided by: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00454701 |
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
Condition | Intervention | Phase |
Psoriasis |
Drug: Alefacept exposure |
Phase IV |
MedlinePlus related topics: | Psoriasis |
Drug Information available for: | Alefacept |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS) |
Estimated Enrollment: | 5000 |
Study Start Date: | July 2003 |
Estimated Study Completion Date: | December 2013 |
Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
1
Patients treated with alefacept for chronic plaque psoriasis
|
Drug: Alefacept exposure
Observational
|
There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients treated with alefacept for chronic plaque psoriasis
Inclusion Criteria:
Contact: Clinsys | 866-285-2755 |
Show 292 Study Locations |
Astellas Pharma Inc |
Study Director: | Use Central Contact | Astellas Pharma US, Inc. |
Responsible Party: | Astellas Pharma US, Inc ( Sr Manager Clinical Trials Registry ) |
Study ID Numbers: | 0485-CL-0001, C-736 |
First Received: | March 29, 2007 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00454701 |
Health Authority: | United States: Institutional Review Board; Canada: Health Canada |
|
|
|